DR-280 Genomic Correlates of Melanoma Outcomes
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-280 Genomic Correlates of Melanoma Outcomes
Recent advances in melanoma treatments have greatly improved patient survival. However, many patients still do not benefit, and we do …
DR-286 Biomarker discovery using machine learning to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment
Immune checkpoint inhibitors (ICIs) have been approved for treatment of metastatic urothelial cancer patients. Unfortunately, treatment response rates are low …
DR-282 A pan-cancer catalogue of the mutational footprint of DNA repair deficiencies and their potential as biomarkers of treatment efficacy
Cancer develops by the accumulation of mutations in the DNA of individual cells. In many patients, DNA repair mechanisms are …
DR-274 Next generation CUP diagnostics by WGS by improving tumor classification categories and re-training
Cancer of unknown primary (CUP) has a worldwide incidence of 3-5% of all cancers diagnoses. The clinical problem of this …
DR-299 MutSig – The incidence and co-ocurrence of genomic biomarkers in metastatic tumors
The observed incidence of cancer biomarkers can influence resource investment into key areas such as drug discovery and companion diagnostic …
DR-277 Somatic mutational signature identification in children with underlying cancer predisposition syndromes
Tumors from children with underlying DNA damage response or DNA repair defects often carry somatic mutational footprints that can aid …
DR-267 The whole-genome landscape of advanced biliary tract cancer
Biliary tract cancer (BTC) is a malignancy of the bile ducts (also called cholangiocarcinoma) and gallbladder. BTC is a rare …
DR-007 Mutational migration determined by sequential sequencing
In this project, pairs of tumor biopsies are requested to study evolution of tumors over time. This project may provide …
DR-006 KRAS mutations as a resistance mechanism in gastrointestinal stromal tumors
The researchers will explore the prevalance of mutations in the KRAS gene in GIST patients and study the response to …
DR-005 HMF-Australia
The goal of this request is to enable Hartwig Medical Foundation Australia team to optimize bio informatic tools and pipelines …
DR-004 Molecular background of chemotherapy respons in ovarian cancer
The goal of this project is to identify genetic factors that are involved in chemotherapy resistence in ovarium cancer and …
DR-003 TUMOROID/SENSOR study
The objective of this request is to connect genetic information obtained in the CPCT-02 study and in vitro tumor organoid …
Zolang de behandelaar niet weet waar de primaire tumor zit, heeft hij ook geen gerichte behandelmogelijkheid en kan ook geen inschatting worden gegeven hoe lang iemand nog heeft.